Association of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study

[1]  Longxuan Li,et al.  Interactions between meropenem and renal drug transporters. , 2022, Current drug metabolism.

[2]  J. Cailhier,et al.  Risk of acute kidney injury associated with anti-pseudomonal and anti-MRSA antibiotic strategies in critically ill patients , 2022, PloS one.

[3]  Sumit K. Agarwal,et al.  Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study. , 2021, Journal of critical care.

[4]  E. Barreto,et al.  Glomerular Function and Urinary Biomarker Changes between Vancomycin and Vancomycin plus Piperacillin-Tazobactam in a Translational Rat Model , 2021, bioRxiv.

[5]  Whitney J. Nesbitt,et al.  Development of the Three Antimicrobial Stewardship E's (TASE) framework and Association between Stewardship Interventions and intended Results (ASIR) analysis to identify key facility-specific interventions and strategies for successful antimicrobial stewardship. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  P. Murray,et al.  Nephrotoxicity from Vancomycin Combined with Piperacillin-Tazobactam: A Comprehensive Review , 2021, American Journal of Nephrology.

[7]  Alan R. Ellis,et al.  Propensity Score Weighting And Trimming Strategies To Reduce Variance And Bias Of Treatment Effect Estimates: A Simulation Study. , 2021, American journal of epidemiology.

[8]  Miao He,et al.  Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model , 2021, Antimicrobial Agents and Chemotherapy.

[9]  Brett H. Heintz,et al.  Risk of acute kidney injury and Clostridioides difficile infection with piperacillin/tazobactam, cefepime and meropenem with or without vancomycin. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  S. Cosgrove,et al.  Significant Regional Differences in Antibiotic Use Across 576 US Hospitals and 11 701 326 Adult Admissions, 2016–2017 , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  V. Pergialiotis,et al.  Acute kidney injury following the concurrent administration of antipseudomonal beta-lactams and vancomycin: a network meta-analysis. , 2020, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  A. Zuppa,et al.  Lack of synergistic nephrotoxicity between vancomycin and piperacillin/tazobactam in a rat model and a confirmatory cellular model. , 2020, The Journal of antimicrobial chemotherapy.

[13]  Jiajun Liu,et al.  Piperacillin-Tazobactam Added to Vancomycin Increases Risk for AKI: Fact or Fiction? , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  J. Kellum,et al.  Evaluating Renal Stress Using Pharmacokinetic Urinary Biomarker Data in Critically Ill Patients Receiving Vancomycin and/or Piperacillin–Tazobactam: A Secondary Analysis of the Multicenter Sapphire Study , 2019, Drug Safety.

[15]  Mark Lunt,et al.  Avoiding pitfalls when combining multiple imputation and propensity scores , 2019, Statistics in medicine.

[16]  Kellyn F Arnold,et al.  Analyses of ‘change scores’ do not estimate causal effects in observational data , 2019, International journal of epidemiology.

[17]  C. Edelstein,et al.  Biomarkers of Drug-Induced Kidney Toxicity , 2022 .

[18]  Xihong Lin,et al.  Plasma angiopoietin-2 as a potential causal marker in sepsis-associated ARDS development: evidence from Mendelian randomization and mediation analysis , 2018, Intensive Care Medicine.

[19]  Huijun Sun,et al.  JBP485 attenuates vancomycin-induced nephrotoxicity by regulating the expressions of organic anion transporter (Oat) 1, Oat3, organic cation transporter 2 (Oct2), multidrug resistance-associated protein 2 (Mrp2) and P-glycoprotein (P-gp) in rats. , 2018, Toxicology letters.

[20]  A. Rule,et al.  Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin. , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Javier A. Neyra,et al.  Risk Prediction Models for Acute Kidney Injury in Critically Ill Patients: Opus in Progressu , 2018, Nephron.

[22]  J. Arthur,et al.  Vancomycin-Associated Acute Kidney Injury with a Steep Rise in Serum Creatinine , 2018, Nephron.

[23]  Huijun Sun,et al.  OAT1 and OAT3 also mediate the drug-drug interaction between piperacillin and tazobactam. , 2018, International journal of pharmaceutics.

[24]  R. Watkins,et al.  Increasing Evidence of the Nephrotoxicity of Piperacillin/Tazobactam and Vancomycin Combination Therapy—What Is the Clinician to Do? , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  J. Farber,et al.  The Nephrotoxicity of Vancomycin , 2017, Clinical pharmacology and therapeutics.

[26]  M. Daudon,et al.  Vancomycin-Associated Cast Nephropathy. , 2017, Journal of the American Society of Nephrology : JASN.

[27]  Richard Evans,et al.  Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin–Tazobactam Compared to Those on Vancomycin and Cefepime , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  E. Wijdicks,et al.  Cefepime neurotoxicity in the intensive care unit: a cause of severe, underappreciated encephalopathy , 2013, Critical Care.

[29]  Ognjen Gajic,et al.  Risk Factors for Development of Acute Kidney Injury in Critically Ill Patients: A Systematic Review and Meta-Analysis of Observational Studies , 2012, Critical care research and practice.

[30]  Gavin J Becker.  Work Group Membership , 2012, Kidney international supplements.

[31]  Harold I Feldman,et al.  Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.

[32]  Michael A Rose,et al.  A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. , 2012, American journal of physiology. Renal physiology.

[33]  J. Schildcrout,et al.  Estimating baseline kidney function in hospitalized patients with impaired kidney function. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[34]  Chirag R Parikh,et al.  Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. , 2012, Kidney international.

[35]  J. Margolick,et al.  Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the Cytometric Bead Array. , 2011, Journal of immunological methods.

[36]  R. Bellomo,et al.  Cystatin C in acute kidney injury , 2010, Current opinion in critical care.

[37]  J. Pickering,et al.  Rapid detection of acute kidney injury by plasma cystatin C in the intensive care unit. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  M. Lipsitch,et al.  Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies , 2010, Epidemiology.

[39]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[40]  Christopher H Schmid,et al.  Factors other than glomerular filtration rate affect serum cystatin C levels. , 2009, Kidney international.

[41]  U. Holzgrabe,et al.  Inhibition of flucloxacillin tubular renal secretion by piperacillin. , 2008, British journal of clinical pharmacology.

[42]  J. Rello,et al.  Impact of diversity of antibiotic use on the development of antimicrobial resistance. , 2006, The Journal of antimicrobial chemotherapy.

[43]  A. Kribben,et al.  Early detection of acute renal failure by serum cystatin C. , 2004, Kidney international.

[44]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[45]  Ashutosh Kumar Singh,et al.  Suspected Acute Interstitial Nephritis Induced by Piperacillin‐Tazobactam , 1997, Pharmacotherapy.

[46]  P. Sokol.  Mechanism of vancomycin transport in the kidney: studies in rabbit renal brush border and basolateral membrane vesicles. , 1991, The Journal of pharmacology and experimental therapeutics.

[47]  J. Bauer,et al.  Clinical appraisal of creatinine clearance as a measurement of glomerular filtration rate. , 1982, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[48]  M. Kollef,et al.  Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam, Cefepime, or Meropenem , 2019, Antimicrobial Agents and Chemotherapy.

[49]  Christopher X. Wong,et al.  AKI and Long-Term Risk for Cardiovascular Events and Mortality. , 2017, Journal of the American Society of Nephrology : JASN.

[50]  Norbert Lameire,et al.  Notice , 2012, Kidney International Supplements.

[51]  S. Hennessy,et al.  Combined Vancomycin and Piperacillin-Tazobactam Treatment Is Not Associated with Acute Kidney Injury (AK) When Assessed Using Plasma Cystatin C , 2022, A3. A003 MICROBIOME, DISPARITIES, COVID-19, AND MORE: CRITICAL CARE HOT TOPICS.